Endothelial Dysfunction in Type 2 Diabetes Mellitus

Indian Journal of Clinical Biochemistry

Volumn 31, Issue 4, 2016, Pages 372-379

  Dhananjayan, R ^a   Koundinya, K S Srivani ^b   Malati, T ^c   Kutala, Vijay Kumar ^c  

^a ACS Medical College and Hospital   (India)

^b MEENAKSHI AMMAL DENTAL COLLEGE AND HOSPITAL   (India)

^c NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Endothelial dysfunction; eNOS; IRS 1; Oxidative stress; Type 2 diabetes mellitus

Indexed keywords

BIOLOGICAL MARKER;

ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; GENETICS; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; REVIEW;

EID: 84944692016     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-015-0516-y     Document Type: Review

References (62)

1. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917–23.
2. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med. 1998;105:32S–9S.
3. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J mol cell Cardiol. 1999;31:61–74.
4. Furchgott RF. Albert Lasker medical research awards the discovery of endothelium—derived relaxing factor and its importance in the identification of nitric oxide. JAMA. 1996;276:1186–8.
5. Kawashima S. The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium. 2004;11:99–107.
6. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA. 1996;93:9114–9.
7. Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kB. Free Radic Biol Med. 2000;28:1317–27.
8. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546–9.
9. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153–7.
10. Avogaro A, Albiero M, Menegazzo L, Kreutzenberg SD, Fadini GP. Endothelial dysfunction in diabetes—the role of reparatory mechanisms. Diabetes Care. 2011;34(2):285–90.
11. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010;11(1):61–74.
12. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:1209–15.
13. Oyama J, Higashi Y, Node K. Do incretins improve endothelial function? Cardiovasc Diabetol. 2014;13:21.
14. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002;87:563–8.
15. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.
16. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.
17. Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol. 1997;80(9A):11I–6I.
18. Trichon BH, Roe MT. Diabetes mellitus and ischemic heart disease. In: Marso SP, Stern DM, editors. Diabetes and cardiovascular disease integrating science and clinical medicine. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 355–78.
19. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473–81.
20. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract. 2003;61(Suppl 1):S9–18.
21. Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab. 2003;88:1417–27.
22. Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem. 1998;273:34724–9.
23. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low-density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512–9.
24. Drab M, Verkade P, Elger M. Loss of caveolae, vascular dysfunction and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449–52.
25. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High-density lipoprotein prevents oxidized low-density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000;275:11278–83.
26. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047–52.
27. Tummala PE, Chen XL, Sundell CL. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin angiotensin system and atherosclerosis. Circulation. 1999;100:1223–9.
28. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus. Report of a WHO Consultation Geneva 1999, p. 43–46.
29. Grundy SM, Brewer HB Jr., Cleeman JI, Smith SC Jr., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific Issues related to definition. Circulation. 2004; 109:433–438.
30. McVeigh GE, Cohn JN. Endothelial dysfunction and the metabolic syndrome. Curr Diab Rep. 2003;3:87–92.
31. Toikka JO, Ahotupa M, Viikari JSA, Niinikoski H, Taskinen MT, Irjala K, et al. Constantly low HDL cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999;147:133–8.
32. Pieper GM, Langenstroer P, Siebeneich W. Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovasc Res. 1997;34:145–56.
33. Hazel L, Kenneth A, Roebuck O. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol. 2001;280:C719–41.
34. Maejima K, Nakano S, Himeno M, Tsuda S, Makiishi H, Ito T, et al. Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects relationship to microvascular complications. J Diabetes Complic. 2001;15:135–43.
35. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24:816–23.
36. Su Y, Liu XM, Sun YM, Jin HB, Fu R, Wang YY, et al. The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int J Clin Pract. 2008;62:877–82.
37. Peerapatdit T, Patchanans N, Likidlilid A, Poldee S, Sriratanasathavorn C. Plasma lipid peroxidation and antioxidant nutrients in type 2 diabetic patients. J Med Assoc Thai. 2006;89:S147–55.
38. Bloomer RJ. Decreased blood antioxidant capacity and increased lipid peroxidation in young cigarette smokers compared to nonsmokers: impact of dietary intake. Nutr J. 2007;6:39.
39. Keenoy BMY, Vertommen J, De Leeuw I. Divergent effects of different oxidants on glutathione homeostasis and protein damage in erythrocytes from diabetic patients: effects of high glucose. Mol Cell Biochem. 2001;225:59–73.
40. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res. 2004;95:233–8.
41. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 1990;173(3):932–9.
42. Arese P, Schwarzer E. Metabolic disorders: red cell alterations in diabetes mellitus. Berlin: Springer; Red cell membrane transport in health and disease 2003; 22:525–526.
43. Nwose EU, Jelinek HF, Richards RS, Kerr PG. Changes in the erythrocyte glutathione concentration in the course of diabetes mellitus. Redox Rep. 2006;11(3):99–104.
44. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813–8.
45. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet. 2005;565:610–2.
46. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens. 2005;14:33–7.
47. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci. 2000;902:230–9.
48. Vita JA, Treasure CB, Nabel EG, Mclenachan JM, Fish RD, Yeung AC, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81(2):491–7.
49. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041–6.
50. Gaeta G, De Michele M, Cuomo S, Guarini P, Fogila MC, Bond MG, et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med. 2000;343:840–6.
51. Giugliano D, Ceriello A, Esposito K. Glucose metabolism and hyperglycemia. Am J Clin Nutr. 2008;87:217S–22S.
52. Williams S. The association of the Glu298Asp polymorphism of endothelial nitric oxide synthase (eNOS) with outcome after subarachnoid hemorrhage. Doris Duke Med Stud J. 2003–2004;3:52–56.
53. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int. 2000;57:405–13.
54. Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Sud K, Bhansali A, et al. Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians. Mol Cell Biochem. 2008;314:9–17.
55. Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE. Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis. 2002;162(2):391–7.
56. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene. 2000;19(49):5574–81.
57. Zang Y, Wat N, Stratton IM, Warren-Perry MG, Orho M, Groop L, et al. UKPDS19: heterogeneity in NIDDM: separate contribution of IRS-1 and beta3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. Diabetologia. 1996;39:1505–11.
58. Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, Accili D, et al. The Gly3Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab. 2000;85:2004–13.
59. Federici M, Hribal ML, Ranalli M, Marselli L, Porzio O, Lauro R, et al. The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. FASEB J. 2001;15:22–4.
60. Holzl B, Iglseder B, Stadlmayr A, Hedegger M, More E, Reiter R, et al. Intima media thickness of carotid arteries is reduced in heterozygous carriers of the Gly972Arg variant in the insulin receptor substrate-1 gene. Eur J Clin Invest. 2003;33(2):110–6.
61. Dhananjayan R, Malati T, Brindha G, Kutala VK. Association of family history of type 2 diabetes mellitus with markers of endothelial dysfunction in South Indian population. Indian J Biochem Biophys. 2013;50:93–8.
62. Schalkwijk CG, Stehouwer CDA. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143–59.